Published in J Exp Med on August 01, 1995
Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev (2011) 5.15
Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. PLoS Med (2007) 2.54
Common strategies for antigenic variation by bacterial, fungal and protozoan pathogens. Nat Rev Microbiol (2009) 2.54
Humoral responses to Plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa. Infect Immun (2007) 2.01
The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro. Infect Immun (1998) 2.00
Antibodies to Plasmodium falciparum antigens predict a higher risk of malaria but protection from symptoms once parasitemic. J Infect Dis (2011) 1.98
Current status of malaria and potential for control. Clin Microbiol Rev (2001) 1.92
Target antigen, age, and duration of antigen exposure independently regulate immunoglobulin G subclass switching in malaria. Infect Immun (2006) 1.87
Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect Immun (2005) 1.83
Malaria in humans: Plasmodium falciparum blood infection levels are linked to chromosome 5q31-q33. Am J Hum Genet (1998) 1.78
Cohort study of the association of antibody levels to AMA1, MSP119, MSP3 and GLURP with protection from clinical malaria in Ghanaian children. Malar J (2008) 1.76
A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. PLoS Med (2005) 1.75
High immunoglobulin G2 (IgG2) and low IgG4 levels are associated with human resistance to Plasmodium falciparum malaria. Infect Immun (2000) 1.73
Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria. BMC Med (2014) 1.71
Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal. Infect Immun (2000) 1.68
The importance of human FcgammaRI in mediating protection to malaria. PLoS Pathog (2007) 1.61
Antibodies to the N-terminal block 2 of Plasmodium falciparum merozoite surface protein 1 are associated with protection against clinical malaria. Infect Immun (2004) 1.60
Transforming growth factor beta production is inversely correlated with severity of murine malaria infection. J Exp Med (1998) 1.57
Human malaria in immunocompromised mice: an in vivo model to study defense mechanisms against Plasmodium falciparum. J Exp Med (2000) 1.50
Fcgamma receptor-mediated phagocytosis of Plasmodium falciparum-infected erythrocytes in vitro. Clin Exp Immunol (2002) 1.48
Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adults. PLoS One (2008) 1.46
Clinical protection from falciparum malaria correlates with neutrophil respiratory bursts induced by merozoites opsonized with human serum antibodies. PLoS One (2010) 1.46
Differential patterns of human immunoglobulin G subclass responses to distinct regions of a single protein, the merozoite surface protein 1 of Plasmodium falciparum. Infect Immun (2001) 1.44
Acquisition of Functional Antibodies That Block the Binding of Erythrocyte-Binding Antigen 175 and Protection Against Plasmodium falciparum Malaria in Children. Clin Infect Dis (2015) 1.42
In vitro growth-inhibitory activity and malaria risk in a cohort study in mali. Infect Immun (2009) 1.39
Repeat sequences in block 2 of Plasmodium falciparum merozoite surface protein 1 are targets of antibodies associated with protection from malaria. Infect Immun (2003) 1.37
Interleukin-10 responses to liver-stage antigen 1 predict human resistance to Plasmodium falciparum. Infect Immun (1999) 1.34
World Malaria Day 2009: what malaria knows about the immune system that immunologists still do not. J Immunol (2009) 1.32
A reduced risk of infection with Plasmodium vivax and clinical protection against malaria are associated with antibodies against the N terminus but not the C terminus of merozoite surface protein 1. Infect Immun (2006) 1.27
The quantity and quality of African children's IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malaria. PLoS One (2009) 1.24
Hemozoin (malarial pigment) directly promotes apoptosis of erythroid precursors. PLoS One (2009) 1.21
Immunogenicity and in vitro protective efficacy of a recombinant multistage Plasmodium falciparum candidate vaccine. Proc Natl Acad Sci U S A (1999) 1.19
Schistosomiasis coinfection in children influences acquired immune response against Plasmodium falciparum malaria antigens. PLoS One (2010) 1.17
Elevated serum levels of IL-1ra in children with Plasmodium falciparum malaria are associated with increased severity of disease. Cytokine (2008) 1.12
How might infant and paediatric immune responses influence malaria vaccine efficacy? Parasite Immunol (2009) 1.11
Pattern of humoral immune response to Plasmodium falciparum blood stages in individuals presenting different clinical expressions of malaria. Malar J (2008) 1.10
Cytophilic antibodies to Plasmodium falciparum glutamate rich protein are associated with malaria protection in an area of holoendemic transmission. Malar J (2005) 1.10
CD36-mediated nonopsonic phagocytosis of erythrocytes infected with stage I and IIA gametocytes of Plasmodium falciparum. Infect Immun (2003) 1.09
A distinct peripheral blood monocyte phenotype is associated with parasite inhibitory activity in acute uncomplicated Plasmodium falciparum malaria. PLoS Pathog (2009) 1.09
Immunization with a combination of merozoite surface proteins 4/5 and 1 enhances protection against lethal challenge with Plasmodium yoelii. Infect Immun (2002) 1.08
Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months. Malar J (2009) 1.08
Antibodies protect against intracellular bacteria by Fc receptor-mediated lysosomal targeting. Proc Natl Acad Sci U S A (2010) 1.07
Regulation of antigen-specific immunoglobulin G subclasses in response to conserved and polymorphic Plasmodium falciparum antigens in an in vitro model. Infect Immun (2002) 1.05
Protective properties and surface localization of Plasmodium falciparum enolase. Infect Immun (2007) 1.04
Identification of a novel antigen of Schistosoma mansoni shared with Plasmodium falciparum and evaluation of different cross-reactive antibody subclasses induced by human schistosomiasis and malaria. Infect Immun (2006) 1.04
Naturally acquired humoral and cellular immune responses to Plasmodium vivax merozoite surface protein 9 in Northwestern Amazon individuals. Vaccine (2008) 1.03
Fc-receptors and immunity to malaria: from models to vaccines. Parasite Immunol (2009) 1.02
Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children. PLoS One (2009) 1.02
Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria. Infect Immun (2002) 1.02
Merozoite surface proteins in red blood cell invasion, immunity and vaccines against malaria. FEMS Microbiol Rev (2016) 1.02
High levels of IgG3 anti ICB2-5 in Plasmodium vivax-infected individuals who did not develop symptoms. Malar J (2013) 1.02
Protection against Plasmodium chabaudi malaria induced by immunization with apical membrane antigen 1 and merozoite surface protein 1 in the absence of gamma interferon or interleukin-4. Infect Immun (2004) 1.00
Polymorphism of the Fcgamma receptor IIA and malaria morbidity. J Mol Genet Med (2005) 0.96
Different regions of the malaria merozoite surface protein 1 of Plasmodium chabaudi elicit distinct T-cell and antibody isotype responses. Infect Immun (2001) 0.96
Human recombinant antibodies against Plasmodium falciparum merozoite surface protein 3 cloned from peripheral blood leukocytes of individuals with immunity to malaria demonstrate antiparasitic properties. Infect Immun (2006) 0.95
Link between immune response and parasite synchronization in malaria. Proc Natl Acad Sci U S A (2003) 0.95
Mixed allele malaria vaccines: host protection and within-host selection. Vaccine (2008) 0.94
Fc γ receptor IIIB (FcγRIIIB) polymorphisms are associated with clinical malaria in Ghanaian children. PLoS One (2012) 0.94
Inhibitory antibodies specific for the 19-kilodalton fragment of merozoite surface protein 1 do not correlate with delayed appearance of infection with Plasmodium falciparum in semi-immune individuals in Vietnam. Infect Immun (2009) 0.94
Flow cytometric readout based on Mitotracker Red CMXRos staining of live asexual blood stage malarial parasites reliably assesses antibody dependent cellular inhibition. Malar J (2012) 0.94
Complement contributes to protective immunity against reinfection by Plasmodium chabaudi chabaudi parasites. Infect Immun (2001) 0.94
Strain-transcending Fc-dependent killing of Plasmodium falciparum by merozoite surface protein 2 allele-specific human antibodies. Infect Immun (2010) 0.93
Malaria resistance genes are associated with the levels of IgG subclasses directed against Plasmodium falciparum blood-stage antigens in Burkina Faso. Malar J (2012) 0.93
Toward the rational design of a malaria vaccine construct using the MSP3 family as an example: contribution of antigenicity studies in humans. Infect Immun (2009) 0.92
Efficient measurement of opsonising antibodies to Plasmodium falciparum merozoites. PLoS One (2012) 0.92
Antibodies against ribosomal phosphoprotein P0 of Plasmodium falciparum protect mice against challenge with Plasmodium yoelii. Infect Immun (2000) 0.92
Opsonization and phagocytosis of Plasmodium falciparum merozoites measured by flow cytometry. Clin Diagn Lab Immunol (2000) 0.92
Acquisition of antibodies to merozoite surface protein 3 among residents of Korogwe, north eastern Tanzania. BMC Infect Dis (2010) 0.92
Epitope-specific regulation of immunoglobulin class switching in mice immunized with malarial merozoite surface proteins. Infect Immun (2005) 0.91
Phagocytosis does not play a major role in naturally acquired transmission-blocking immunity to Plasmodium falciparum malaria. Infect Immun (1999) 0.91
Assessment of the neutrophilic antibody-dependent respiratory burst (ADRB) response to Plasmodium falciparum. J Leukoc Biol (2014) 0.91
Plasmodium falciparum serine repeat protein, a new target of monocyte-dependent antibody-mediated parasite killing. Infect Immun (2002) 0.89
Identification of a vaccine candidate antigen, PfMAg-1, from Plasmodium falciparum with monoclonal antibody M26-32. Parasitol Res (2009) 0.89
Plasmodium falciparum merozoite surface protein 1 (MSP-1)-MSP-3 chimeric protein: immunogenicity determined with human-compatible adjuvants and induction of protective immune response. Infect Immun (2009) 0.89
Antigenicity of recombinant proteins derived from rhoptry-associated protein 1 of Plasmodium falciparum. Infect Immun (1998) 0.88
T cell epitope regions of the P. falciparum MSP1-33 critically influence immune responses and in vitro efficacy of MSP1-42 vaccines. PLoS One (2011) 0.88
Functional haplotypes of Fc gamma (Fcγ) receptor (FcγRIIA and FcγRIIIB) predict risk to repeated episodes of severe malarial anemia and mortality in Kenyan children. Hum Genet (2011) 0.88
Novel approaches to identify protective malaria vaccine candidates. Front Microbiol (2014) 0.87
Isolation, production and characterization of fully human monoclonal antibodies directed to Plasmodium falciparum MSP10. Malar J (2015) 0.86
Lack of avidity maturation of merozoite antigen-specific antibodies with increasing exposure to Plasmodium falciparum amongst children and adults exposed to endemic malaria in Kenya. PLoS One (2012) 0.85
Sequence variation of PfEMP1-DBLalpha in association with rosette formation in Plasmodium falciparum isolates causing severe and uncomplicated malaria. Malar J (2009) 0.84
Assessment of antibody-dependent respiratory burst activity from mouse neutrophils on Plasmodium yoelii malaria challenge outcome. J Leukoc Biol (2013) 0.84
Specific antibody responses against membrane proteins of erythrocytes infected by Plasmodium falciparum of individuals briefly exposed to malaria. Malar J (2010) 0.83
Protective epitopes of the Plasmodium falciparum SERA5 malaria vaccine reside in intrinsically unstructured N-terminal repetitive sequences. PLoS One (2014) 0.83
Sequence conservation in Plasmodium falciparum alpha-helical coiled coil domains proposed for vaccine development. PLoS One (2009) 0.83
Progress and prospects for blood-stage malaria vaccines. Expert Rev Vaccines (2016) 0.82
Subclass responses and their half-lives for antibodies against EBA175 and PfRh2 in naturally acquired immunity against Plasmodium falciparum malaria. Malar J (2014) 0.82
Cytokine profiles at birth predict malaria severity during infancy. PLoS One (2013) 0.82
Pretreatment with Cry1Ac protoxin modulates the immune response, and increases the survival of Plasmodium-infected CBA/Ca mice. J Biomed Biotechnol (2010) 0.81
Transgenic rodent Plasmodium berghei parasites as tools for assessment of functional immunogenicity and optimization of human malaria vaccines. Eukaryot Cell (2008) 0.81
Platform for Plasmodium vivax vaccine discovery and development. Mem Inst Oswaldo Cruz (2011) 0.81
T-cell and serological responses to Erp, an exported Mycobacterium tuberculosis protein, in tuberculosis patients and healthy individuals. BMC Infect Dis (2007) 0.81
Antibodies to malaria vaccine candidates are associated with chloroquine or sulphadoxine/pyrimethamine treatment efficacy in children in an endemic area of Burkina Faso. Malar J (2012) 0.80
Intermittent preventive treatment with sulfadoxine-pyrimethamine does not modify plasma cytokines and chemokines or intracellular cytokine responses to Plasmodium falciparum in Mozambican children. BMC Immunol (2012) 0.80
Comparative Immunogenicities of full-length Plasmodium falciparum merozoite surface protein 3 and a 24-kilodalton N-terminal fragment. Clin Vaccine Immunol (2011) 0.80
Synchronization of Plasmodium falciparum erythrocytic stages in culture. J Parasitol (1979) 23.90
Gamma-globulin and acquired immunity to human malaria. Nature (1961) 13.07
Tumor necrosis factor and disease severity in children with falciparum malaria. N Engl J Med (1989) 6.79
TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria. Lancet (1990) 6.32
Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J Exp Med (1990) 5.04
Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature (1994) 4.37
Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg (1991) 4.16
Rapid identification of monocytes in a mixed mononuclear cell preparation. J Immunol Methods (1977) 4.12
Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity. Infect Immun (1992) 3.42
Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood (1994) 3.05
Cultivation of malarial parasites. Nature (1978) 3.05
Protection of mice against Babesia and Plasmodium with BCG. Nature (1976) 3.01
Immune interferon induces the receptor for monomeric IgG1 on human monocytic and myeloid cells. J Exp Med (1983) 2.93
Human monocytes and U937 cells bear two distinct Fc receptors for IgG. J Immunol (1986) 2.53
Cytotoxicity mediated by human Fc receptors for IgG. Immunol Today (1989) 2.47
Anti-TNF therapy inhibits fever in cerebral malaria. Q J Med (1993) 2.47
Synergism between tumor necrosis factor-alpha and interferon-gamma on macrophage activation for the killing of intracellular Trypanosoma cruzi through a nitric oxide-dependent mechanism. Eur J Immunol (1992) 1.96
Direct access to serum macromolecules by intraerythrocytic malaria parasites. Nature (1991) 1.72
Plasmodium falciparum: isolation and purification of spontaneously released merozoites by nylon membrane sieves. Exp Parasitol (1982) 1.70
Cytokines kill malaria parasites during infection crisis: extracellular complementary factors are essential. J Exp Med (1991) 1.69
Effector cells involved in nonspecific and antibody-dependent mechanisms directed against Plasmodium falciparum blood stages in vitro. Infect Immun (1989) 1.61
Molecular variation in a novel polymorphic antigen associated with Plasmodium falciparum merozoites. Mol Biochem Parasitol (1994) 1.60
Serum containing tumor necrosis factor is cytotoxic for the human malaria parasite Plasmodium falciparum. Infect Immun (1983) 1.60
Epidemiological correlation between levels of antibodies promoting merozoite phagocytosis of Plasmodium falciparum and malaria-immune status. Infect Immun (1987) 1.48
Cytokine-mediated inactivation of malarial gametocytes is dependent on the presence of white blood cells and involves reactive nitrogen intermediates. Immunology (1993) 1.41
Activation of monocytes and platelets by monoclonal antibodies or malaria-infected erythrocytes binding to the CD36 surface receptor in vitro. J Clin Invest (1989) 1.36
In vitro and in vivo studies on protective and inhibitory antibodies against Plasmodium falciparum in the Saimiri monkey. J Immunol (1984) 1.29
Antagonistic and additive effects of IL-4 and interferon-gamma on human monocytes and macrophages: effects on Fc receptors, HLA-D antigens, and superoxide production. Cell Immunol (1990) 1.27
Direct evidence for an intracellular role for tumor necrosis factor-alpha 1. Microinjection of tumor necrosis factor kills target cells. J Immunol (1990) 1.22
Antibody-dependent ingestion of P. falciparum merozoites by human blood monocytes. Parasite Immunol (1983) 1.12
Cross-linking of monocyte plasma membrane Fc alpha, Fc gamma or mannose receptors induces TNF production. Immunology (1993) 1.06
Structure-activity studies of human tumour necrosis factors. Protein Eng (1994) 1.06
Generation of reactive oxygen species in whole blood from patients with acute falciparum malaria. Parasite Immunol (1987) 1.01
Immunity to blood stages of malaria. Curr Opin Immunol (1993) 1.01
Malaria vaccines. Curr Opin Immunol (1992) 0.99
Activation of phagocyte oxidative metabolism by opsonized Plasmodium falciparum merozoites. Acta Trop (1990) 0.90
Human monocyte-mediated cytotoxicity towards erythrocytes induced by hybrid mouse monoclonal antibodies: effect of antibody binding valency on IgG-Fc gamma R interaction. Immunology (1992) 0.90
Investigation of the effect of monocytes with Papua New Guinea sera on Plasmodium falciparum in culture. Int J Parasitol (1988) 0.85
Induction of tumor necrosis factor alpha by Leishmania infantum in murine macrophages from different inbred mice strains. Microb Pathog (1992) 0.85
Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J Exp Med (1990) 5.04
Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg (1991) 4.16
Vector density gradients and the epidemiology of urban malaria in Dakar, Senegal. Am J Trop Med Hyg (1992) 3.71
Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity. Infect Immun (1992) 3.42
Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood (1994) 3.05
Fast emergence of Plasmodium falciparum resistance to halofantrine. Lancet (1993) 3.03
Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nat Med (2000) 2.70
Malaria: even more chronic in nature than previously thought; evidence for subpatent parasitaemia detectable by the polymerase chain reaction. Trans R Soc Trop Med Hyg (1996) 2.65
Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro. Parasite Immunol (1999) 2.39
Levels of antibodies to Plasmodium falciparum sporozoite surface antigens reflect malaria transmission rates and are persistent in the absence of reinfection. Infect Immun (1986) 2.14
Hepatitis C virus genotyping by means of 5'-UR/core line probe assays and molecular analysis of untypeable samples. Virus Res (1995) 2.14
Transmission of hepatitis B virus by HBV-negative blood transfusion. Lancet (1995) 2.06
A liver-stage-specific antigen of Plasmodium falciparum characterized by gene cloning. Nature (1987) 2.02
The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro. Infect Immun (1998) 2.00
Pattern of immunoglobulin isotype response to Plasmodium falciparum blood-stage antigens in individuals living in a holoendemic area of Senegal (Dielmo, west Africa). Am J Trop Med Hyg (1996) 1.98
Effect of antibodies to recombinant and synthetic peptides on P. falciparum sporozoites in vitro. Science (1986) 1.81
Rapid turnover of Plasmodium falciparum populations in asymptomatic individuals living in a high transmission area. Am J Trop Med Hyg (1996) 1.76
Cooperation between antibodies and monocytes that inhibit in vitro proliferation of Plasmodium falciparum. Infect Immun (1983) 1.74
Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal. Infect Immun (2000) 1.68
Effector cells involved in nonspecific and antibody-dependent mechanisms directed against Plasmodium falciparum blood stages in vitro. Infect Immun (1989) 1.61
Complete development of hepatic stages of Plasmodium falciparum in vitro. Science (1985) 1.58
Natural antibody response to Plasmodium falciparum Exp-1, MSP-3 and GLURP long synthetic peptides and association with protection. Parasite Immunol (2004) 1.51
Human malaria in immunocompromised mice: an in vivo model to study defense mechanisms against Plasmodium falciparum. J Exp Med (2000) 1.50
Epidemiological correlation between levels of antibodies promoting merozoite phagocytosis of Plasmodium falciparum and malaria-immune status. Infect Immun (1987) 1.48
Enhanced Plasmodium falciparum merozoite phagocytosis by monocytes from immune individuals. Infect Immun (1982) 1.46
Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus. Gut (1999) 1.44
Evaluation under field conditions of the colourimetric DELI-microtest for the assessment of Plasmodium falciparum drug resistance. Trans R Soc Trop Med Hyg (2001) 1.42
Impact of TT virus infection in acute and chronic, viral- and non viral-related liver diseases. J Hepatol (2000) 1.40
Non-organ specific autoantibodies associated with chronic C virus hepatitis. J Hepatol (1993) 1.39
Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests. Gastroenterol Clin Biol (2008) 1.39
Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. Eur J Immunol (1997) 1.39
[Eradication of hepatitis C virus after 3 months of interferon treatment in a patient with chronic hepatitis C]. Gastroenterol Clin Biol (2000) 1.38
Malaria morbidity among children exposed to low seasonal transmission in Dakar, Senegal and its implications for malaria control in tropical Africa. Am J Trop Med Hyg (1993) 1.34
Cultivation of the liver forms of Plasmodium vivax in human hepatocytes. Nature (1984) 1.33
Evaluation of an in vitro assay aimed at measuring protective antibodies against sporozoites. Bull World Health Organ (1990) 1.30
Species- and stage-specific antigens in exoerythrocytic stages of Plasmodium falciparum. Am J Trop Med Hyg (1984) 1.30
Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity. J Gen Virol (1998) 1.27
Impaired cell-mediated immunity in Plasmodium falciparum-infected patients with high-parasitemia and cerebral malaria. Clin Immunol Immunopathol (1983) 1.26
Multi-drug resistant falciparum malaria in Cameroon in 1987-1988. I. Stable figures of prevalence of chloroquine- and quinine-resistant isolates in the original foci. Am J Trop Med Hyg (1992) 1.26
Antibodies in falciparum malaria: what matters most, quantity or quality? Mem Inst Oswaldo Cruz (1992) 1.23
Novel DNA assay for cytomegalovirus detection: comparison with conventional culture and pp65 antigenemia assay. J Clin Microbiol (1996) 1.17
A novel Plasmodium falciparum sporozoite and liver stage antigen (SALSA) defines major B, T helper, and CTL epitopes. J Immunol (1996) 1.16
A novel merozoite surface antigen of Plasmodium falciparum (MSP-3) identified by cellular-antibody cooperative mechanism antigenicity and biological activity of antibodies. Mem Inst Oswaldo Cruz (1994) 1.16
Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients. J Hepatol (1997) 1.15
Immunization of Saimiri sciureus monkeys with Plasmodium falciparum merozoite surface protein-3 and glutamate-rich protein suggests that protection is related to antibody levels. Scand J Immunol (2004) 1.14
[Immuno-electro-diffusion on cellulose acetate membrane for serological testing in human malaria (author's transl)]. Pathol Biol (Paris) (1978) 1.14
Conservation and heterogeneity of the glutamate-rich protein (GLURP) among field isolates and laboratory lines of Plasmodium falciparum. Mol Biochem Parasitol (2000) 1.14
Parasite-derived mitogenic activity for human T cells in Plasmodium falciparum continuous cultures. Infect Immun (1981) 1.13
Antibody-dependent ingestion of P. falciparum merozoites by human blood monocytes. Parasite Immunol (1983) 1.12
The interferon compartment of the immune response in human malaria: II. Presence of serum-interferon gamma following the acute attack. J Interferon Res (1985) 1.11
Premunition against Plasmodium falciparum in a malaria hyperendemic village in Myanmar. Trans R Soc Trop Med Hyg (2001) 1.11
Antagonism of chloroquine with other antimalarials. Trans R Soc Trop Med Hyg (1988) 1.10
Protection against malaria induced by irradiated sporozoites. Lancet (1990) 1.10
Selection of glutamate-rich protein long synthetic peptides for vaccine development: antigenicity and relationship with clinical protection and immunogenicity. Infect Immun (2001) 1.10
Plasmodium falciparum sporozoite invasion is inhibited by naturally acquired or experimentally induced polyclonal antibodies to the STARP antigen. Eur J Immunol (1997) 1.10
Identification of a major B-cell epitope of the Plasmodium falciparum glutamate-rich protein (GLURP), targeted by human antibodies mediating parasite killing. Vaccine (2000) 1.09
Multi-drug resistant falciparum malaria in Cameroon in 1987-1988. II. Mefloquine resistance confirmed in vivo and in vitro and its correlation with quinine resistance. Am J Trop Med Hyg (1992) 1.05
High immunogenicity in chimpanzees of peptides and lipopeptides derived from four new Plasmodium falciparum pre-erythrocytic molecules. Vaccine (2000) 1.05
Immune mechanisms underlying the premunition against Plasmodium falciparum malaria. Mem Inst Oswaldo Cruz (1994) 1.03
Patterns of in vitro resistance to chloroquine, quinine, and mefloquine of Plasmodium falciparum in Cameroon, 1985-1986. Am J Trop Med Hyg (1988) 1.02
Naturally acquired human antibodies which recognize the first epidermal growth factor-like module in the Plasmodium falciparum merozoite surface protein 1 do not inhibit parasite growth in vitro. Infect Immun (1994) 1.02
High titres of anti-T antibodies and other haemagglutinins in human malaria. Clin Exp Immunol (1982) 1.02
Generation of reactive oxygen species in whole blood from patients with acute falciparum malaria. Parasite Immunol (1987) 1.01
Vaccine potentials of an intrinsically unstructured fragment derived from the blood stage-associated Plasmodium falciparum protein PFF0165c. Infect Immun (2009) 1.01
Circulating interferon in patients with Plasmodium falciparum, P. ovale and P. vivax malaria. Trans R Soc Trop Med Hyg (1982) 1.01
Essential mixed cryoglobulinemia. A comparative study of dermatologic manifestations in patients infected or noninfected with hepatitis C virus. Arch Dermatol (1995) 1.01
HCV infection in a rural population of the Central African Republic (CAR): evidence for three additional subtypes of genotype 4. J Med Virol (1995) 1.01
High level of sensitivity to chloroquine of 72 Plasmodium falciparum isolates from southern Cameroon in January 1985. Am J Trop Med Hyg (1986) 1.01
Hepatitis C virus and autoimmunity: fortuitous association or reality? Gastroenterology (1994) 1.01
Plasmodium falciparum in vitro culture: improvements using umbilical cord serum and medium modifications. Tropenmed Parasitol (1980) 1.00
Long synthetic peptides encompassing the Plasmodium falciparum LSA3 are the target of human B and T cells and are potent inducers of B helper, T helper and cytolytic T cell responses in mice. Eur J Immunol (2001) 0.99
The Plasmodium falciparum knob-associated PfEMP3 antigen is also expressed at pre-erythrocytic stages and induces antibodies which inhibit sporozoite invasion. Mol Biochem Parasitol (2001) 0.99
Human lymphocyte responses to Plasmodium falciparum merozoite antigens. A functional assay of protective immunity? Trans R Soc Trop Med Hyg (1985) 0.98
Rodent malaria in the natural host--irradiated sporozoites of Plasmodium berghei induce liver-stage specific immune responses in the natural host Grammomys surdaster and protect immunized Grammomys against P. berghei sporozoite challenge. Afr J Med Med Sci (2001) 0.97
Human malaria in immunocompromised mice: new in vivo model for chemotherapy studies. Antimicrob Agents Chemother (2001) 0.97
DNA immunization by Plasmodium falciparum liver-stage antigen 3 induces protection against Plasmodium yoelii sporozoite challenge. Infect Immun (2001) 0.97
Impairment of Plasmodium falciparum-specific antibody response in severe malaria. J Clin Microbiol (1990) 0.97
Fast immunopurification of small amounts of specific antibodies on peptides bound to ELISA plates. J Immunol Methods (1993) 0.96
[Epidemiologic and virologic study of hepatitis C virus infections in Morocco]. Gastroenterol Clin Biol (2000) 0.96
Anti-malaria humoral responses in children exposed to Plasmodium falciparum and Schistosoma haematobium. Mem Inst Oswaldo Cruz (2007) 0.96
Evidence for diversity of Plasmodium falciparum sporozoite surface antigens derived from analysis of antibodies elicited in humans. Infect Immun (1990) 0.95
Testing for HCV-RNA in commercial intravenous immunoglobulins. Lancet (1993) 0.94
Malaria diagnosis: standardization of a polymerase chain reaction for the detection of Plasmodium falciparum parasites in individuals with low-grade parasitemia. Parasitol Res (1996) 0.94
FibroMeters: a family of blood tests for liver fibrosis. Gastroenterol Clin Biol (2008) 0.93
Effect on antibody and T-cell responses of mixing five GMP-produced DNA plasmids and administration with plasmid expressing GM-CSF. Genes Immun (2004) 0.92
Human antibodies against Plasmodium falciparum liver-stage antigen 3 cross-react with Plasmodium yoelii preerythrocytic-stage epitopes and inhibit sporozoite invasion in vitro and in vivo. Infect Immun (2001) 0.92
Expression of the erythrocyte-binding antigen 175 in sporozoites and in liver stages of Plasmodium falciparum. J Infect Dis (2001) 0.92
Immunogenicity of four Plasmodium falciparum preerythrocytic antigens in Aotus lemurinus monkeys. Infect Immun (1998) 0.92
Plasmodium falciparum: studies on mature exoerythrocytic forms in the liver of the chimpanzee, Pan troglodytes. Exp Parasitol (1990) 0.91
Aspects of immunity for the AMA-1 family of molecules in humans and non-human primates malarias. Mem Inst Oswaldo Cruz (1994) 0.91
Secondary structure and immunogenicity of hybrid synthetic peptides derived from two Plasmodium falciparum pre-erythrocytic antigens. J Immunol (1990) 0.91
Activation of phagocyte oxidative metabolism by opsonized Plasmodium falciparum merozoites. Acta Trop (1990) 0.90
Three cases of severe subfulminant hepatitis in heart-transplanted patients after nosocomial transmission of a mutant hepatitis B virus. Hepatology (1999) 0.90